CuraTeQ Biologics Secures CDSCO Approval for Bevqolva
CuraTeQ Biologics receives CDSCO marketing authorisation for Bevqolva, strengthening its oncology biosimilars portfolio and expanding access to advanced cancer therapies.
Bevacizumab Biosimilar Approval | 16/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy